Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Invasive Breast Cancer × Cyclophosphamide × Clear all

Phase

Phase 3 2 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 223 Lymphoma 214 Precursor Cell Lymphoblastic Leukemia-Lymphoma 173 Leukemia 159 Lymphoma, Large B-Cell, Diffuse 153 Multiple Myeloma 151 Lymphoma, Non-Hodgkin 136 Leukemia, Lymphocytic, Chronic, B-Cell 133 Leukemia, Myeloid, Acute 121 Hodgkin Disease 106 Myelodysplastic Syndromes 105 Lymphoma, Follicular 104 Burkitt Lymphoma 100 Lymphoma, Mantle-Cell 95 Lymphoma, B-Cell, Marginal Zone 70 Lymphoma, Large-Cell, Immunoblastic 61 Neoplasms, Plasma Cell 56 Recurrence 55 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 50 Myeloproliferative Disorders 46 Dendritic Cell Sarcoma, Interdigitating 45 Leukemia, Myeloid, Chronic-Phase 44 Leukemia, Myeloid, Accelerated Phase 44 Neoplasms 43 Melanoma 42 Leukemia, Myelomonocytic, Chronic 42 Waldenstrom Macroglobulinemia 37 Triple Negative Breast Neoplasms 37 Blast Crisis 36 Congenital Abnormalities 35

Interventions

liposomal doxorubicin 1 cemiplimab 1 Paclitaxel 1 Doxorubicin 1 Cyclophosphamide 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04243616 2025-09-05

CemiHALT

Medical College of Wisconsin

Phase 2 Active not recruiting

Invasive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡